Page 11234..1020..»

Category Archives: Stem Cell Research

Canine Stem Cell Therapy Market Research 2021-2027 With VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics -…

Posted: August 18, 2021 at 2:47 am

The updated report on the Canine Stem Cell Therapy market gives a precise analysis of the value chain assessment for the review period of 2021 to 2027. The research includes an exhaustive evaluation of the administration of the key market companies and their revenue-generating business strategies adopted by them to drive sustainable business. The Service industry report further enlists the market shortcomings, stability, growth drivers, restraining factors, opportunities for the projected timeframe.

Get Sample Report with Latest Industry Trends Analysis:

https://www.a2zmarketresearch.com/sample?reportId=21262

The top companies in this report include:

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos.

The Global Canine Stem Cell Therapy market is expected to register a notable market expansion of XX% during the review period owing to the largest market value in 2019. The market study provides a measure of the effectiveness of the product, real-time Canine Stem Cell Therapy market scenario, along custom ease. The study further offers market analysis, strategies and planning, R & D landscape, target audience management, market potential, due diligence, and competitive landscape.

Scope of the report:

A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Canine Stem Cell Therapy market dynamics. The report includes Porters Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report spans the Canine Stem Cell Therapy research data of various companies, benefits, gross margin, strategic decisions of the worldwide market, and more through tables, charts, and infographics.

The Canine Stem Cell Therapy report highlights an all-inclusive assessment of the revenue generated by the various segments across different regions for the forecast period, 2021 to 2027. To leverage business owners, gain a thorough understanding of the current momentum, the Canine Stem Cell Therapy research taps hard to find data on aspects including but not limited to demand and supply, distribution channel, and technology upgrades. Principally, the determination of strict government policies and regulations and government initiatives building the growth of the Canine Stem Cell Therapy market offers knowledge of what is in store for the business owners in the upcoming years.

Request For Customized Report:

https://www.a2zmarketresearch.com/enquiry?reportId=21262

Geographic analysis

The global Canine Stem Cell Therapy market has been spread across North America, Europe, Asia-Pacific, the Middle East and Africa, and the rest of the world.

COVID-19 Impact Analysis

The pandemic of COVID-19 has emerged in lockdown across regions, line limitations, and breakdown of transportation organizations. Furthermore, the financial vulnerability Canine Stem Cell Therapy Market is a lot higher than past flare-ups like the extreme intense respiratory condition (SARS), avian influenza, pig influenza, bird influenza, and Ebola, inferable from the rising number of contaminated individuals and the vulnerability about the finish of the crisis. With the rapid rising cases, the worldwide Canine Stem Cell Therapy refreshments market is getting influenced from multiple points of view.

The accessibility of the labor force is by all accounts disturbing the inventory network of the worldwide Canine Stem Cell Therapy drinks market as the lockdown and the spread of the infection are pushing individuals to remain inside. The presentation of the Canine Stem Cell Therapy makers and the transportation of the products are associated. If the assembling movement is stopped, transportation and, likewise, the store network additionally stops. The stacking and dumping of the items, i.e., crude materials and results (fixings), which require a ton of labor, is likewise vigorously affected because of the pandemic. From the assembling plant entryway to the stockroom or from the distribution center to the end clients, i.e., application ventures, the whole Canine Stem Cell Therapy inventory network is seriously compromised because of the episode.

The research provides answers to the following key questions:

Buy Exclusive Report:

https://www.a2zmarketresearch.com/buy?reportId=21262

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Organic Bananas Market Witness Growth Acceleration | Fyffes Ltd, Coliman Group, Exporganic, Del Monte Fresh Produce Co.

Visit link:
Canine Stem Cell Therapy Market Research 2021-2027 With VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics -...

Posted in Stem Cell Research | Comments Off on Canine Stem Cell Therapy Market Research 2021-2027 With VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics -…

Coloradans Getting Third Dose Of COVID Vaccine Say They Feel More Protected Than Ever – CBS Denver

Posted: at 2:47 am

LOVELAND, Colo. (CBS4) Some of the first Coloradans to get a third dose of the COVID-19 vaccine say they feel more protected than ever before from the deadly virus. Coloradans who are immunocompromised have been granted permission to get a third dose of the Pfizer or Moderna vaccines in order to increase the efficacy of the vaccines. Those considered healthy have not been granted authorization for so-called booster shots as of the posting of this article.

I have absolutely gotten the COVID vaccine. My first, my second and now my third, said Betsy Craig, a Northern Colorado resident living with Scleroderma.

Craig was diagnosed in 2005 with Scleroderma and was only given 18 months to survive. However, a stem cell transplant helped her regain longevity and a mostly normal lifestyle.

However, viruses ranging from the common flu to COVID-19 pose a real threat to her life.

Because of her weakened immune system, Craigs two doses of vaccine did not give her the roughly 95% efficacy which most vaccinated people with two doses have. So, the CDC and FDA approved people like Craig to receive a third dose of either the Moderna or Pfizer vaccine to increase their protection.

I called the third dose liquid gold, because to me it is. It is the closest thing to protection to keep me breathing, Craig told CBS4s Dillon Thomas.

Dr. Thomas Campbell, Chief Clinical Research Officer for UCHealth, said the vaccines are effective but will need boosters over time.

The primary series we currently do of two doses doesnt work well enough, Campbell said.

Campbell said, once approved by the FDA, vaccinated Americans will likely need to receive routine booster shots to continue to maintain high rates of immunity.

The Pfizer and Moderna vaccines can protect people up to 96%. Compared to the annual flu shot, which only protects people about 50% of the time from the flu, the vaccines are incredibly effective.

However, like other vaccines, they can lose strength over time. Tetanus shots need boosting every 10 years, while flu shots often need to be boosted every year.

Preliminary research shows the COVID-19 Pfizer and Moderna vaccines will likely need boosters every eight months.

Campbell said, currently, only the immunocompromised need their third doses of the vaccines.

Those individuals never achieve adequate immunity with just two doses. They need a third dose just to get to adequate immunity, Campbell said. That is in contrast to people who are otherwise healthy, they respond well to the two-dose series. But, we know from immerging data, the protection wains over time. This doesnt mean the vaccine doesnt work. It just means that it can work better if we give it a third dose.

When getting a third dose of vaccine Coloradans will not have to return to the place they received their initial doses. Experts say there wont be an issue with availability due to demand as we saw when the vaccines first surfaced.

Also, while highly recommended, it isnt required for people to get the same type of vaccine they did for the first two. Campbell said Pfizer and Moderna can be mixed over time if absolutely necessary.

While the FDA works on rolling out booster shots for regularly healthy people, Craig said she is thrilled to have more protection from the virus.

(Forgoing the third dose) is Russian roulette, and I am just not willing to play Russian roulette if I dont have to. It is just relief that I am not going to die if I get sick, Craig said.

Link:
Coloradans Getting Third Dose Of COVID Vaccine Say They Feel More Protected Than Ever - CBS Denver

Posted in Stem Cell Research | Comments Off on Coloradans Getting Third Dose Of COVID Vaccine Say They Feel More Protected Than Ever – CBS Denver

3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along…

Posted: at 2:47 am

VANCOUVER, BC, Aug. 17, 2021 /PRNewswire/ -- The global 3D bioprinting market size is expected to reach USD 2,687.8 Million in 2027 at a CAGR of 20.7% during the forecast period, according to the recent report by Emergen Research. Rapid technological advancements in 3D bioprinters, increasing investment to accelerate research and development activities of bioprinters, and rising use of 3D bioprinters to develop biomaterials for drug research and regeneration of joints and ligaments are key factors expected to drive market revenue growth over the forecast period. In addition, numerous advantages of 3D bioprinting in organ reconstruction to treat various end-stage disorders is another key factor contributing to the revenue growth of the market.

3D bioprinting leverages techniques similar to additive manufacturing to mix up growth factors, cells, and biomaterials to create biomedical parts that can mimic natural tissue attributes. 3D bioprinting leverages layer-by-layer technique to add materials called as bioinks to create tissue-like structures that can be used in medical and tissue engineering procedures. Recent advancements in the technique has expanded its scope in drug design and development by creating target tissues and cells for drug research and testing. In addition, 3D bioprinters can be used to reconstruct tissues from any body part and this has further increased its applications for treating various severe and chronic disorders. Significant progress in tissue engineering and production of biomaterials have contributed considerably to the 3D bioprinting market growth.

Download FREE Sample Brochure (Customized Sample PDF File delivered as per your specific requirement)@https://www.emergenresearch.com/request-sample/133

3D bioprinters have been extensively used in vaccine research during the COVID-19 pandemic. Bioprinting is widely being used in the development of regenerative medicines, stem cell therapies, drug research and therapies, and tissue and organ reconstruction. Increasing application of 3D bioprinting in cosmetic and pharmaceutical sector is also a key factor contributing to the revenue growth of the market going ahead. However, lack of skilled professionals and technical knowledge, high costs of 3D bioprinting, and limited access to advanced technologies in developing and underdeveloped countries are some key factors expected to restrain market growth to a significant extent over the forecast period.

Some Key Highlights in the Report:

Buy your Exclusive copy [Make Payment ]@ https://www.emergenresearch.com/select-license/133

For the purpose of this report, Emergen Research has segmented the global 3D bioprinting market on the basis of technology, material, application, and region:

Technology Outlook (Revenue, USD Million; 2017-2027)

Material Outlook (Revenue, USD Million; 2017-2027)

Application Outlook (Revenue, USD Million; 2017-2027)

Have a look at Report Description and Table of Contents of Market Research [emailprotected] https://www.emergenresearch.com/industry-report/3d-bioprinting-market

Regional Outlook (Revenue, USD Million; 2017-2027)

Explore more reports offered by Emergen Research:

The Global Oncology Informatics Market size was valued at USD 4.62 Billion in 2019 and is anticipated to reach USD 8.01 Billion by 2027 at a CAGR of 7.1%. An increase in the awareness of the different types of treatment options for oncology will drive the demand for the oncology informatics market. The major driving factor is the rise in the prevalence of cancer and heavy investment by the government institutes and research organizations.

The Global Nerve Repair and Regeneration Market size was valued at USD 6.05 Billion in 2019 and is forecasted to reach USD 11.62 Billion by 2027 at a CAGR of 9.0%. The market is mainly driven by the rising geriatric population and the increasing prevalence of nerve injuries. The high incidence of neurological disorders among the growing population is expected to drive the Nerve Repair and Regeneration Market growth.

The Global Spinal Fusion Devices Market size was valued at USD 6.88 Billion in 2019 and is forecasted to reach USD 8.90 Billion by 2027 at a CAGR of 3.5%. The market is mainly driven by the increasing aging population and their growing need for spine care. Advancements in surgical technology is a key contributing factor behind the increasing demand for spinal fusion devices over the forecast period.

The Global Interventional Oncology Devices Market size was valued at USD 1.92 Billion in 2019 and is expected to reach USD 3.11 Billion by 2027 at a CAGR of 6.6%. The global Interventional Oncology Devices market is forecasted to expand exponentially owing to the rising preference for minimally invasive surgical procedures. The increasing government initiatives to support Interventional Oncology is anticipated to further propel the market growth over the forecasted timeframe.

The global spinal implants and surgery devices market size was valued at USD 10.22 Billion in 2019 and is forecasted to reach USD 14.70 Billion by 2027 at a CAGR of 4.6%. The spinal implants and surgery devices market is observing high demand owing to factors including the rising occurrence of spinal disorders, a rise in the elderly population, growing inclination for less invasive surgery, and growing research activities for developing technologically updated in spinal devices.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:Eric LeeCorporate Sales SpecialistEmergen Research | Web: http://www.emergenresearch.comDirect Line: +1 (604) 757-9756E-mail: [emailprotected]Facebook| LinkedIn| Twitter| Blogs

Read Full Press [emailprotected] https://www.emergenresearch.com/press-release/global-3d-bioprinting-market

SOURCE Emergen Research

Visit link:
3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along...

Posted in Stem Cell Research | Comments Off on 3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along…

What is Stem Cell Research? – WorldAtlas

Posted: July 6, 2021 at 2:49 am

Stem cells are those that don't have a specific purpose.

A stem cell is a cell in a living body with the potential to develop into different types of cells during the early stage. Most cells in a living organism are differentiated cells, meaning they are found in a specific organ and perform particular functions. Red blood cells, for example, are specifically designed to transport oxygen through the blood. Human beings start out as a single cell known as a zygote, which is a fertilized egg. The zygote undergoes cell division into two, then four, eight, sixteen, and so on. The cells begin to differentiate and specialize in specific functions in the body as the zygote develops. The cells that haven't acquired specific purpose are known as stem cells; they can replicate indefinitely unlike differentiated cells that begin to break down after replicating. Once a stem cell divides, it remains as a stem cell or turns into a differentiated cell. This makes them especially intriguing for scientific research.

There are two types of stem cells: embryonic and adult stem cells. Embryonic stem cells are derived from embryos developed through in vitro fertilization in a fertilization clinic. The fertilized eggs are then donated for research purpose with the consent of the donors. Embryonic stem cells develop into specialized cells as the embryo develops. Adult stem cells are found among differentiated cells in an organ or tissue. Their main functions are to repair and maintain the tissue. Unlike embryonic stem cells that are produced by the embryo, researchers are still trying to understand the source of adult stem cells.

Stem cells have three distinct properties regardless of their source; they replicate and renew themselves infinitely, they are unspecialized, and they give rise to differentiated cells. Unlike a nerve cell, blood cells, or muscle cells, stem cells can proliferate. Research conducted in laboratories have revealed that stem cells can yield millions of unspecialized cells with the properties of the parent stem cell.

The properties of stem cells make them excellent and intriguing candidates for research. The embryonic human stem cells provide information concerning the complex process that occurs during the development of life. The primary objective of the research is to understand how undifferentiated cells end up with specific functions. Human stem cells are used to test new drugs and observe how a human body would respond to the medication. Stem cells are also helping researchers study diseases such as cancer and diabetes and how they can be treated. The immediate potential application of stem cell research is the generation of tissues and cells that replace organs once destroyed or removed. A breakthrough would eliminate the dependency on organ transplant, but instead, patients would receive stem cells that would generate the organ. Preliminary research in rodents shows that transplanted stem cells from the bone marrow can generate heart muscle tissues and repair the heart. A bone marrow transplant is already being used as a treatment for some form of cancer in humans.

Read more:
What is Stem Cell Research? - WorldAtlas

Posted in Stem Cell Research | Comments Off on What is Stem Cell Research? – WorldAtlas

New global guidelines for stem cell research aim to drive …

Posted: at 2:49 am

The International Society for Stem Cell Research (ISSCR) today released updated guidelines for stem cell research and its translation to medicine.

Developed in response to recent scientific and clinical advances, the revised guidelines provide a series of detailed and practical recommendations that set out global standards for how these emerging technologies should be harnessed.

Stem cell research has huge potential it could help pave the way for new therapies for ailments ranging from Parkinsons disease to childhood kidney failure. But scientific advances in this field can present unique ethical and policy issues beyond that seen in other areas of medical research.

The science is advancing at breakneck pace. Just in the past couple of months, we have seen model human embryos grown from skin cells, and the creation of human-monkey embryos for use in research.

The ISSCR has long recognised the need to set clear ethical boundaries for stem cell research. Previous guidelines have provided advice on techniques such as the use of human embryos to create stem cells, and set the required standards when using these technologies to create new medicines.

They have also explicitly banned certain practices, such as reproductive cloning and the sale of unproven therapies that claim to be made of stem cells.

The 2021 guidelines an update on the previous version, released in 2016 aim to set standards for the many recent advances in stem cell and human embryo research. These include chimeric embryos containing cells from humans and other animals, organoids grown from stem cells to create tissue that resembles particular human organs, and models of human embryos arrangements of human cells that mimic the early stages of embryo development.

The guidelines contain a clear requirement for certain new stem cell research approaches only to be conducted after a specialised review process. This review should be independent of the researchers, and include community members as well as people with expertise in the relevant science, ethics and law.

This is beyond what is typically required by a university or research institute where medical research is conducted. Besides evaluating the merit of the proposed research, the new reviews should also consider whether there are alternative ways to do the research, the source of stem cells and how they were obtained, and the minimum time required to reach the research goals, particularly in relation to human embryo and related research.

Specialised review is not a new concept. The previous guidelines required it when researchers made stem cells from human embryos or sought to culture human embryos in the lab. But now researchers will now also be required to seek higher review when they create model embryos such as blastoids, or study the development of animal-human embryos in animal wombs.

Researchers developing new therapies for mitochondrial disease will also be required to seek higher-level review before attempting to transfer to the uterus of a woman human embryos in which affected mitochondria (a part of the cells energy-production apparatus) have been replaced.

Importantly, the revised guidelines also clearly rule out certain activities. These continue to include reproductive cloning and attempts to form a pregnancy in a woman from genetically edited human embryos or from model embryos made from stem cells. Prohibited activities also now include using eggs and sperm made from human stem cells for reproduction, or transferring a human-animal chimeric embryo into the uterus of a woman or an ape.

Read more: China's failed gene-edited baby experiment proves we're not ready for human embryo modification

The guidelines also call for a public conversation about whether we should allow limited lab research on human embryos beyond the existing limit of 14 days development. Historically, it has not been possible to support human embryonic development outside the body beyond this stage. However, recent advances in human embryo culture raise the possibility that this may now be technically feasible.

Extending the amount of time in culture - in terms of days - could potentially yield new treatments for developmental conditions or infertility, but will also raise concerns about whether possible benefits justify this research. Any decisions to overturn this long-held signpost would need to be carefully deliberated and take into consideration existing law, community values and discussion around what the new limit should be.

The revised guidelines also reinforce the need for informed consent for the collection of human material and participation in stem cell clinical trials, and reiterate that no new stem cell treatment should be made available before it is tested for safety and effectiveness in well-designed and publicly visible clinical trials. The ISSCR continues to condemn the commercial use of unproven stem cell treatments.

While stem cell science holds much promise, it is paramount that research is scientifically and ethically rigorous, with appropriate oversight, transparency and public accountability.

The fact these guidelines are driven by experts including stem cell scientists, doctors, ethicists, lawyers and industry representatives from across 14 countries indicates a deep sense of responsibility and integrity within the research community, and a desire to ensure science remains in step with community values.

However, these guidelines are recommendations, not laws.

Researchers will need to abide by their respective national or state regulations and ethical standards. Some countries already have regulatory frameworks that are consistent with the new recommendations. In other places there is no national guidance around laboratory and clinical stem cell research at all, or existing law touches on some but not all of the emerging applications of stem cell research.

Read more: As scientists move closer to making part human, part animal organisms, what are the concerns?

For example, in Australia there is already an established pathway for higher-level review of embryo models created from stem cells. However, the same legislation currently bans any attempt to use mitochondrial transfer techniques to create embryos for research or to achieve a pregnancy both of which are permissible under the new ISSCR guidelines.

Rather than attempting to impose a set of hard-and-fast rules on an ever-evolving research field, the new guidelines attempt to address emerging issues and drive important discussions at domestic level. Ultimately, it is the public and the regulators who will need to set the standards.

Read more here:
New global guidelines for stem cell research aim to drive ...

Posted in Stem Cell Research | Comments Off on New global guidelines for stem cell research aim to drive …

$6.3 million for ground-breaking stem cell research projects – News – The University of Sydney

Posted: at 2:49 am

The Federal Minister for Health and Aged Care, the Hon Greg Hunt, has announced$18.7 million in funding for the 2020 Stem Cell Mission, which focuses on research that develops and delivers innovative, safe and effective stem cell medicines to improve health outcomes.

Researchers from the University of Sydney have been awarded $6.3 million for three projects which will address blindness in adults, chronic heart failure, and help to improve decisions about access to stem cell interventions.

Deputy-Vice-Chancellor (Research), ProfessorDuncan Ivisoncelebrated the funding success.

This funding will allow our health and medical researchers to undertake important research for the benefit of many Australians and their families, through trials that use stem cell grown heart muscle in patients with no option end-stage heart failure," he said.

Medical Research Future Fund (MRFF) 2020 Stem Cell Mission grants awarded to Sydney researchers include:

The Stem Cell Mission is a priority of the Morrison Governments $20 billion Medical Research Future Fundand will provide $150 million towards research over 9 years.

More:
$6.3 million for ground-breaking stem cell research projects - News - The University of Sydney

Posted in Stem Cell Research | Comments Off on $6.3 million for ground-breaking stem cell research projects – News – The University of Sydney

Limits for human embryo research have been changed: this calls for public debate – The Conversation CA

Posted: at 2:49 am

For 40 years, research into early human development has been guided by the principle that after 14 days, an embryo should not be used for research and must be destroyed. This rule has been part of the law of more than 12 countries. But new guidelines released by the International Society for Stem Cell Research have removed this rule. This makes it possible to conduct research on human embryos that are at more advanced stages of development.

Now, countries must revise their laws, policies and guidelines to reflect this change. But first, public debate is crucial to determine the limits of what sort of research should be allowed.

Over the decades human embryo research has allowed us to understand normal and abnormal human development, as well as early genetic diseases and disorders. Studying human embryos, as the earliest forms of human life, can give us insight into why miscarriages occur, and how our complex body systems develop. Human embryos are also important for stem cell research, where researchers try and create cell-based therapies to treat human diseases.

Often, extra embryos are created during in vitro fertilisation procedures. These extra embryos may be donated for research. They are cultured (or grown) in a laboratory and can be studied until they reach day 14 post-creation.

The 14-day rule has served as an international standard since 1990 when it was included in the Human Fertilisation and Embryology Act in the UK. At the time that it was introduced, it was not possible to keep human embryos alive in a laboratory for more than a few days. However, scientists have been recently been able to keep embryos alive for longer periods, between 12 and 13 days. The ethical, legal and social consequences of such research were also important considerations.

Although the 14-day rule has been criticised as being arbitrarily decided, there are a number of reasons for the time frame.

After an egg cell is fertilised by a sperm cell, the resulting embryo consists of a few identical cells. Most embryos will implant in the uterus after the 14th day. After this point, the primitive streak appears, which is the first sign of an embryos developing nervous system. The rule also identified the point at which the embryo shows signs of individuation, because it is no longer possible for the embryo to split into twins after 14 days. Some people reason that due to these events, it is at this stage that a moral being comes into existence, and it would not be ethical to perform research on embryos after this time.

There has been increasing pressure from some researchers to remove the 14-day rule, or at least extend it, as it prevents critical research from being undertaken. Extending the rule would allow important research into early human development to be done. The new guidelines make it possible to do research on embryos older than 14 days if the approval processes of the relevant ethics committees are followed.

A significant problem, however, is that there is no longer any limit on the time frame for research. Would it be permissible to do research on human embryos that are 20 days old or 40 days old? The guidelines specify no limit. The longer a human embryo is allowed to grow, the more recognisably human it becomes. At what point would we regard the research unethical, and at what point does the moral cost outweigh the benefits of research?

Countries around the world take a variety of approaches to human embryo research. Some like Italy and Germany dont allow it at all. Others, like the UK, allow research to continue until the embryo is 14 days old, after which it must be destroyed. There are also some which permit embryo research without identifying a limit. Some, like the US, do not have any law regulating it (but there are guidelines which contain reference to the 14-day rule).

In South Africa, reference to the rule is found in the National Health Act (2003), which states that human embryo research may only be done with permission of the minister, and that the embryos must not be older than 14 days.

International guidelines are not legally binding. But the effect of the revised guidelines is that the international standard for best practice in scientific research has now changed. This means that countries which have implemented the rule in their laws will need to revise them so that they are in line with best practice in science.

Human embryo research is a sensitive topic because people are divided on the moral status of the human embryo. Some people believe that the embryo, as the earliest form of human life, should be protected and not subjected to research at all. Others believe that while an embryo has some moral status, it cannot be protected in the same way as humans are, and may be used for some important research which could ultimately benefit people.

The decision to discard the 14-rule appears to have been made without public input. That does not encourage the public to trust in science, and public engagement should have come before such an an important rule was changed.

There are a number of approaches to working with the revised guidance. Bioethicist Franoise Baylis has suggested that project-specific time limits should be identified, based on the minimum amount of time required to address the stated research objectives. This would mean that some research would still be subject to the 14-day limit, while other studies would be permitted to exceed it. Another approach would be to keep the 14-day limit as the norm, and consider applications to exceed it case by case. Or the limit could be extended to 28 days.

The coming conversations surrounding embryo research will prove to be very important. The proverbial genie is out of the bottle, and public debate is crucial.

Read this article:
Limits for human embryo research have been changed: this calls for public debate - The Conversation CA

Posted in Stem Cell Research | Comments Off on Limits for human embryo research have been changed: this calls for public debate – The Conversation CA

Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene…

Posted: June 23, 2021 at 2:24 am

REDWOOD CITY, Calif. and NEW YORK and BASEL, Switzerland, June 21, 2021 /PRNewswire/ --Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, andAruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that they have entered a non-exclusive research collaboration to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent with ARU-1801, Aruvant's investigational lentiviral gene therapy for sickle cell disease (SCD). The objective of the collaboration is to evaluate the use of JSP191 as an effective and more tolerable conditioning agent that can expand the number of patients who can receive ARU-1801, a potentially curative treatment for SCD.

"This research collaboration with Aruvant is the first to use a clinical-stage antibody-based conditioning agent and a novel clinical-stage gene therapy, giving this combination a clear advantage by moving beyond the harsh conditioning agents currently used for gene therapy and establishing this next-generation potentially curative treatment as a leader in sickle cell disease," said Kevin N. Heller, M.D., executive vice president, research and development of Jasper. "Our goal is to establish JSP191 as a potential new standard of care conditioning agent, broadly in autologous gene therapy and allogeneic hematopoietic stem cell transplantation."

Gene therapies and gene editing technologies generally require that a patient's own hematopoietic stem cells first be depleted from the bone marrow to facilitate the engraftment of the new, gene-modified stem cells through a process called conditioning. Other investigational gene therapies and gene editing approaches in SCD use a high-dose chemotherapy such as busulfan for the conditioning regimen, which can place patients at prolonged risk for infection and bleeding, secondary malignancy and infertility. ARU-1801 is currently the only gene therapy that has demonstrated durable efficacy using both a lower dose of chemotherapy and a different agent than busulfan with a more limited side effect profile. The Aruvant-Jasper partnership is focused on evaluating the potential of using JSP191, a highly targeted anti-CD117 (stem cell factor receptor) monoclonal antibody agent, as the foundationof a novel conditioning regimen for use in combination with ARU-1801 to further reduce the negative side effects while maintaining efficacy.

"The unique attributes of ARU-1801 enable us to bring a potentially curative one-time therapy to individuals with sickle cell disease that can be delivered in the safest way possible," said Will Chou, M.D., Aruvant chief executive officer. "By partnering with Jasper to evaluate the use of JSP191 with ARU-1801, we are one step closer to developing a next-generation definitive therapy with an even more patient-friendly conditioning regimen. We believe that this combination may be able to further expand the number of patients who can benefit from ARU-1801 in the future, including potentially those with more moderate disease."

About JSP191JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or gene-corrected transplanted stem cells to engraft. While hematopoietic cell transplantation can be curative for patients, its use is limited because standard high dose myeloablative conditioning is associated with severe toxicities and standard low dose conditioning has limited efficacy. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients. It is currently enrolling in two clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and severe combined immunodeficiency (SCID) and expects to begin enrollment in four additional studies in 2021 for severe autoimmune disease, sickle cell disease, chronic granulomatous disease and Fanconi anemia patients undergoing hematopoietic cell transplantation.

About ARU-1801ARU-1801 is designed to address the limitations of current curative treatment options, such as low donor availability and the risk of graft-versus-host disease (GvHD) seen with allogeneic stem cell transplants. Unlike investigational gene therapies and gene editing approaches which require fully myeloablative conditioning, the unique characteristics of ARU-1801 allow it to be given with reduced intensity conditioning ("RIC"). Compared to myeloablative approaches, the lower dose chemotherapy regimen underlying RIC has the potential to reduce not only hospital length of stay, but also the risk of short- and long-term adverse events such as infection and infertility. Preliminary clinical data from the MOMENTUMstudy, an ongoing Phase 1/2 trial of ARU-1801 in patients with severe sickle cell disease, demonstrate continuing durable reductions in disease burden.

The MOMENTUM StudyAruvant is conducting the MOMENTUM study, which is evaluating ARU-1801, a one-time potentially curative investigational gene therapy for patients with SCD. This Phase 1/2 study is currently enrolling participants, and information may be found at momentumtrials.comwhich includes a patient brochure, an eligibility questionnaireand information for healthcare providers.

About Jasper TherapeuticsJasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, a first-in-class anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

About Aruvant SciencesAruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases. The company has a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. Aruvant has an active research program with a lead product candidate, ARU-1801, in development for individuals suffering from sickle cell disease (SCD). ARU-1801, an investigational lentiviral gene therapy, is being studied in a Phase 1/2 clinical trial, the MOMENTUM study, as a one-time potentially curative treatment for SCD. Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy. The company's second product candidate, ARU-2801, is in development to cure hypophosphatasia, a devastating, ultra-orphan disorder that affects multiple organ systems and leads to high mortality when not treated. Data from pre-clinical studies with ARU-2801 shows durable improvement in disease biomarkers and increased survival. For more information on the ongoing ARU-1801 clinical study, please visit http://www.momentumtrials.comand for more on the company, please visit http://www.aruvant.com. Follow Aruvant on Facebook, Twitter @AruvantSciencesand on Instagram @Aruvant_Sciences.

About RoivantRoivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants nimble and focused biopharmaceutical and health technology companies. For more information, please visit http://www.roivant.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/jasper-therapeutics-and-aruvant-announce-research-collaboration-to-study-jsp191-an-antibody-based-conditioning-agent-with-aru-1801-a-novel-gene-therapy-for-the-treatment-of-sickle-cell-disease-301316032.html

SOURCE Aruvant Sciences

Originally posted here:
Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene...

Posted in Stem Cell Research | Comments Off on Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene…

Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting – BioSpace

Posted: at 2:24 am

BOSTON, June 17, 2021 /PRNewswire/ -- Next week, June 21-26, stem cell biotechnology company Asymmetrex will participate as a presenter and an exhibitor in the 2021 Annual Meeting of the International Society for Stem Cell Research. In an invited poster presentation (#345) and a company exhibitor display, Asymmetrex will introduce the virtual gathering of international stem cell scientists, physicians, and biotechnologists to its new technology for evaluating the potency of therapeutic tissue stem cells.

Potency tests assure doctors that a medicine has good quality and will be effective for treatment. Although potency tests are common for drug medicines, developing them for stem cell treatments has been difficult. For stem cell treatments, no reliable potency tests have been available.

At the June 21-26, 2021 Annual Meeting of the International Society for Stem Cell Research, stem cell biotechnology company Asymmetrex will present data and examples for a new test for evaluation of the potency of tissue stem cell treatments. The technology, called kinetic stem cell (KSC) counting, can tell doctors the number of live tissue-renewing stem cells in a treatment sample.

The President & CEO of Asymmetrex, James L. Sherley, M.D., Ph.D., explains, "Stem cell medicine has needed a quality and effectiveness index like drug specific activity for pharmaceuticals. What could work better than knowing the number of live tissue stem cells that can restore other tissue cells? That's what our KSC counting TORTOISE TestTM platform can tell doctors: the number of live stem cells in a treatment that can renew an organ or tissue."

Asymmetrex is currently focused on conducting preclinical and clinical evaluations of how well its tissue stem cell-specific data indicate the effectiveness of stem cell treatments in different patients. In his company's presentations at ISSCR 2021, Sherley says that he will also introduce the immediate benefits of KSC counting to stem cell scientists for their tissue stem cell research. "It's a no brainer that now knowing how many tissue stem cells are in experiments will greatly improve stem cell researchand, as a consequence, stem cell medicine."

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio).

Media Contact: James L Sherley, jsherley@asymmetrex.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/asymmetrex-will-present-a-new-test-for-therapeutic-stem-cell-potency-at-the-isscr-2021-annual-meeting-301311815.html

SOURCE Asymmetrex, LLC

See original here:
Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting - BioSpace

Posted in Stem Cell Research | Comments Off on Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting – BioSpace

Stem Cell manufacturing Market All-Inclusive Research Report (20212027) : Includes Impact of COVID-19 The Manomet Current – The Manomet Current

Posted: at 2:24 am

Data Bridge Market Research has recently added a concise research on theGlobal Stem Cell Manufacturing Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated. As per study key players of this market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc and more.

The Global Stem Cell manufacturing Market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.59 billion by 2027 growing at a CAGR of 6.42% in the above-mentioned forecast period. The growing awareness towards diseases like cancer, hematopoietic disorders and degenerative disorders is going to drive the growth of the stem cell manufacturing market.

Download FREE PDF sample copy of this research report@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-market

Global Stem Cell Manufacturing Market, By Product (Stem Cell Line, Instruments, Culture Media, Consumables), Application (Research Applications, Clinical Applications, Cell and Tissue Banking), End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2027

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Major Market competitors/players:Global Stem Cell manufacturing Market

Some of the major players operating in the stem cell manufacturing market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc, Osiris Therapeutics, Osiris Therapeutics, Vericel Corporation, AbbVie, American CryoStem, AM-Pharma, Anterogen.Co.,Ltd, Astellas Pharma, Bristol-Myers Squibb, Apceth Biopharma, Cellular Dynamics International, Rheacell, Takeda Pharmaceutical, Teva Pharmaceutical Industries Ltd. ViaCyte, VistaGen Therapeutics Inc, Translational Biosciences, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, among others.

Market Definition:

This market report defines the market trends and forecast the upcoming opportunities and threats of the stem cell manufacturing market in the next 8 years. Stem cell manufacturing is a process of extracting the cells either from bone marrow or peripheral blood cells and culturing the cells in the culture dish containing nutrient media. Stem cells can be isolated from umbilical cord blood, placenta, amniotic sac, amniotic fluid, adipose tissue and menstrual blood. Stem cell manufacturing is used in the cell therapy as well as in gene therapy. Stem cell therapy is under research for many diseases like degenerative diseases and hematopoietic disorders like sickle cell anemia, storage disorders. Now stem cells are also used in making the cell and tissue bank. Some of the cell culture banks are National Institute of Biomedical Innovation, Health and Nutrition and World Federation for Culture Collections.

Key Insights in the report:

Inquire about this report from our experts @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market

Opportunities in the market

Major Market Drivers:

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sopan.gedam@databridgemarketresearch.com

Read the rest here:
Stem Cell manufacturing Market All-Inclusive Research Report (20212027) : Includes Impact of COVID-19 The Manomet Current - The Manomet Current

Posted in Stem Cell Research | Comments Off on Stem Cell manufacturing Market All-Inclusive Research Report (20212027) : Includes Impact of COVID-19 The Manomet Current – The Manomet Current

Page 11234..1020..»